BMO Capital maintains Outperform on Beam Therapeutics stock
BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears undervalued ...
AZ Central20d
Economists: Phoenix, U.S. economies are solid, but interest rates still plague housing
The Phoenix economy, and that of the nation ... Michael Gregory, deputy chief economist at BMO Capital Markets, said he expects U.S. economic growth to slow slightly from an estimated 2.8% last ...
InvestmentNews29d
BMO Capital Markets to pay $40M in SEC settlement
BMO Capital Markets has agreed to pay more than $40 million to settle charges brought by the SEC for failing to supervise employees involved in the sale of mortgage-backed securities. In a ...
Reuters29d
BMO Capital markets settles with SEC over bond desk supervision
Jan 13 (Reuters) - BMO Capital Markets (BMO.TO), opens new tab agreed to pay more than $40 million to settle U.S. Securities and Exchange Commission charges it failed to properly supervise ...
Fortinet price target raised to $122 from $100 at BMO Capital
BMO Capital analyst Keith Bachman raised the firm’s price target on Fortinet (FTNT) to $122 from $100 but keeps a Market Perform rating on the ...